14 results about "Scavenger receptor" patented technology

In various embodiments tolerogenic nanoparticles are provided that induce immune tolerance to one or more desired antigen(s) and / or that reduce an immune response to those antigen(s). In certain embodiments the tolerogenic nanoparticle comprises a nanoparticle comprising a biocompatible polymer; an antigen disposed within or attached to said biocompatible polymer where said antigen comprises an antigen to which immune tolerance is to be induced by administration of said tolerogenic nanoparticle to a mammal; and a first targeting moiety that binds to a scavenger receptor in the liver, and / or a second targeting moiety that binds to a mannose receptor in the liver, and / or a third targeting moiety that binds to hepatocytes, wherein said first and / or second and / or third targeting moiety are attached to the surface of said nanoparticle.

To provide a method for reducing cholesterol.SOLUTION: There is provided an agent which promotes expression of a class B scavenger receptor which is expressed on a lymphatic vessel endothelial cell. The expression decreases with age. More specifically, at least one plant extract selected from the group consisting of a camellia seed extract, a rosemary extract, a Chinese blackberry tea extract, and a citrus unshiu peel extract is identified as a component which promotes the expression of the class B scavenger receptor, resulting in provision of an expression promoter for the scavenger receptor.SELECTED DRAWING: Figure 1

The invention belongs to the technical field of genetic engineering of animal molecular breeding, and particularly relates to application of a scavenger receptor SCARA3 in resisting H9N2 subtype avian influenza virus (AIV) infection. The invention discovers that the expression quantity of the SCARA3 gene in the DF-1 cell infected by the H9N2 AIV is obviously reduced. The silent SCARA3 can significantly inhibit the replication of the H9N2 avian influenza virus in host cells, which indicates that the SCARA3 gene is a susceptible gene of the H9N2 AIV, and the gene knockdown / knockout can significantly improve the resistance of chicken to the H9N2 AIV. The SCARA3 gene provided by the invention can be used as a target spot for resisting replication of the H9N2 subtype avian influenza virus, can be used as a disease-resistant molecular marker, is used for carrying out assistant breeding on new varieties resisting infection of the H9N2 subtype avian influenza virus, and has important application value in genetic assistant disease-resistant breeding.

Protein-targeted degradation chimeras, their preparation methods, and applications are shown below: #imgabs0#, where R1 is a polythymidine dendrimer DNA, and R2 is an EGFR / NCL antibody and aptamer drug targeting the tumor cell membrane surface. This invention utilizes scavenger receptors as endocytic receptors for the first time, inducing degradation of target proteins through endocytosis. By regulating the levels of pathogenic proteins, this approach achieves benefits in disease research, cancer cell growth inhibition, and tumor treatment. This invention utilizes chemical methods to synthesize dendrimer DNA-based protein-targeted degradation drugs and applies them to research on the targeted degradation of proteins in cells and the regulation of protein levels in cells.

The invention discloses an artificial antigen, an anti-sheep scavenger receptor polyclonal antibody prepared from the artificial antigen and application of the anti-sheep scavenger receptor polyclonal antibody, and belongs to the technical field of immunity. Specifically, firstly, a sheep collagen-like structure macrophage receptor (MARCO) antigen is screened through antigen structure design, and the amino acid sequence of the sheep collagen-like structure macrophage receptor (MARCO) antigen is shown as SEQ ID NO.4. When the antigen is used for immunizing and preparing the antibody, the generated polyclonal antibody is high in titer and strong in specificity. Subsequently, an ELISA detection method for sheep MARCO is established based on the prepared polyclonal antibody, the polyclonal antibody is used as a coating antibody, an HRP-labeled donkey anti-goat antibody is used as a detection antibody, and the detection sensitivity of MARCO in a host is high. Therefore, a new original element is provided for MARCO detection, and the constructed MARCO detection method can effectively assist in screening and diagnosis of the mycoplasma ovipneumoniae.

The application belongs to the technical field of immunology, and particularly relates to a sheep scavenger receptor A antigen polypeptide, a polyclonal antibody thereof, a preparation method and application, and an amino acid sequence of the sheep SRA antigen polypeptide is KSLDEKQVHLEQELKG. A rabbit SRA polyclonal antibody is prepared by using the antigen polypeptide, the rabbit SRA polyclonal antibody has good reactivity and specificity, and can be used for detecting the sheep SRA protein.

Provided is use of scavenger receptor class A member 3 or a reagent increasing the expression of scavenger receptor class A member 3 in preparing a hypoglycemic product. By means of overexpressing a human-derived SR-A3 gene in hamsters, it was found that the overexpression of the human-derived SR-A3 gene can reduce the plasma glucose concentration, decrease the plasma insulin concentration, improve glucose tolerance, enhance insulin sensitivity, reduce insulin resistance, lower the expression of gluconeogenesis-related genes, and inhibit the activation of the AKT signaling pathway. The present application provides a new target and a new strategy for the precise treatment of patients with hyperglycemia.

The invention belongs to the field of research and development of tumor drugs, and discloses a degradable spherical nucleic acid for delivering a protein drug across a blood-brain barrier, aiming at the urgent problems that the protein drug is difficult to cross the blood-brain barrier, poor in targeting property and the like when being delivered to brain tumors, and the invention discloses a degradable spherical nucleic acid for delivering a protein drug across the blood-brain barrier. The surface of the inner core is connected with a nucleic acid aptamer through a covalent bond to form a spherical nucleic acid structure. Protein drugs are delivered through the spherical nucleic acid structure, and benefited from the scavenger receptor mediated cell transfer effect, the main barrier, namely the blood-brain barrier, in brain delivery can be effectively overcome; meanwhile, due to packaging of the protein medicine, the protein medicine is prevented from being released in blood in advance, the possibility that the protein medicine is cleared away in advance is reduced, and the risk that the protein medicine causes adverse immune response is also reduced. Moreover, according to the degradable spherical nucleic acid for delivering the protein medicine across the blood brain barrier, the delivery variety of the spherical nucleic acid is expanded, the retention risk of the spherical nucleic acid is reduced through the idea of responsive degradation, and the degradable spherical nucleic acid has a good application prospect.

The application discloses a monoclonal antibody for identifying human soluble scavenger receptor A, and the amino acid sequences of the heavy chain and the light chain variable region are shown as SEQ ID NO. 1 and SEQ ID NO. 5. A double antibody sandwich detection method is established by using the monoclonal antibody as a capture antibody, the whole operation time is shortened from the conventional 4 hours to 1.5 hours, the detection P / N value is significantly improved, the minimum detection limit reaches 15 pg / mL, and the detectable range is 15-7680 ng / mL. The method is suitable for human soluble scavenger receptor A detection.

To provide compositions, kits and methods for detecting preclinical Alzheimer's disease.SOLUTION: Compositions and kits for diagnosing and prognosing Alzheimer's Disease (AD) in a human patient include a binding agent such as a monoclonal antibody for a biomarker conjugated to a detectable moiety such as a fluorophore, where the biomarker is chosen from CD163, CD91, CD59, MerTK and other phagocytosis-related molecules. Further, compositions and kits employ panels of fluorophore-conjugated monoclonal antibodies for biomarkers including scavenger receptors. Methods for determining the relative expression of biomarkers, diagnosing AD, and determining the efficacy of AD therapeutic candidates such as phagocytosis-promoting agents and scavenger receptor agonists also appear.SELECTED DRAWING: None

The invention provides an application of eplerenone in preparation of a medicine for treating rheumatoid arthritis. The eplerenone can effectively improve imaging characteristics of a rheumatoid arthritis mouse model and reduce levels of C-reactive protein and immune cell scavenger receptors in serum of the rheumatoid arthritis mouse model, and a new drug choice is provided for treatment of rheumatoid arthritis.

Compositions and kits for diagnosing and prognosing Alzheimer's Disease (AD) in a human patient include a binding agent such as a monoclonal antibody for a biomarker conjugated to a detectable moiety such as a fluorophore, wherein the biomarker is chosen from CD163, CD91, CD59, MerTK and other phagocytosis-related molecules. Further compositions and kits employ panels of fluorophore-conjugated monoclonal antibodies for biomarkers including scavenger receptors. Methods for determining the relative expression of biomarkers, diagnosing AD, and determining the efficacy of AD therapeutic candidates such as phagocytosis-promoting agents and scavenger receptor agonists also appear.

In various embodiments tolerogenic nanoparticles are provided that induce immune tolerance to one or more desired antigen(s) and / or that reduce an immune response to those antigen(s). In certain embodiments the tolerogenic nanoparticle comprises a nanoparticle comprising a biocompatible polymer, a cationic lipid, or a combination thereof; an antigen disposed within or attached to said biocompatible polymer or a nucleic acid encoding said antigen, where said antigen comprises an antigen to which immune tolerance is to be induced by administration of said tolerogenic nanoparticle to a mammal; and a targeting moiety that binds to a scavenger receptor in the liver.

The invention relates to the technical field of animal genetic engineering and animal breeding, in particular to a method for constructing an anti-PRRSV pig based on CRISPR / Cas9 homologous recombination. According to the invention, specific sgRNA and a homologous repair template are designed aiming at the receptor-bound pentasaccharide in an SRCR5 structural domain of a pig CD163 gene, accurate knockout of the receptor-bound pentasaccharide is realized in fibroblast of a pig fetus, homozygous deletion cell clone is obtained, and then the receptor-bound pentasaccharide knockout pig is prepared through a somatic cell nuclear transplantation (SCNT) technology. Compared with a wild control pig, the gene editing pig prepared by the invention has obvious disease resistance to the JXA1 strain and is normal in growth and development. The CD163 scavenger receptor function is reserved to the maximum extent, potential side effects are reduced, and a new breeding material capable of being directly used for resisting PRRSV is provided for the live pig industry.